| |
Agenda |
Tuesday, May 8, 2007 |
| | Plenary Session
Moderator: Jacques Normand, Ph.D.
Director
AIDS Research Program
National Institute on Drug Abuse |
8:30 – 8:45 a.m. |
Welcome and Introduction
Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse
|
| 8:45 – 9:00 a.m. | HIV/AIDS in 2007: A Brief Overview
Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
|
| 9:00 – 9:15 a.m. | NIH AIDS Research Priorities
Jack Whitescarver, Ph.D.
Director
Office of AIDS Research
National Institutes of Health
|
| 9:15 – 9:30 a.m. |
Q & A
|
| 9:30 – 9:55 a.m. |
Drug Abuse Treatment and HIV/AIDS: Challenges and Opportunities
David Metzger, Ph.D.
University of Pennsylvania
|
| 9:55 – 10:20 a.m. |
The Role of Drug Abuse in the Evolving HIV Epidemic
Steffanie Strathdee, Ph.D.
University of California, San Diego
|
| 10:20 – 10:30 a.m. |
Q & A |
| 10:30 – 10:45 a.m. |
Break |
| 10:45 – 11:45 a.m. |
Session 1
Drug Abuse, HIV, and the Brain
Chair: David Shurtleff, Ph.D.
National Institute on Drug Abuse
Neuroeconomics: New Approaches to Risky Decisionmaking
Greg Berns, M.D., Ph.D.
Emory University
Neuroimaging To Predict High-Risk Behaviors in Methamphetamine Users
Martin Paulus, M.D., Ph.D.
University of California, San Diego
NeuroAIDS in Drug Users
Justin McArthur, M.D.
Johns Hopkins University
Methamphetamine and HIV: CNS Effects
Igor Grant, M.D.
University of California, San Diego
|
| 11:45 a.m. – 12:05 p.m. |
Q & A |
| 12:05 – 1:30 p.m. |
Lunch (on your own) |
| 1:30 – 2:15 p.m. |
Session 2
Drug Abuse, HIV, and Sexual Risk Behaviors
Chair: Wilson M. Compton, M.D., M.P.E.
National Institute on Drug Abuse
Behavioral Risk and HIV-1 Molecular Diversity: Making the Connections
Chris Beyrer, M.D.
Johns Hopkins University
Alcohol and HIV Risk Behaviors
Michael Stein, M.D.
Brown University
Methamphetamine Use and HIV
Grant Colfax, M.D.
San Francisco Department of Public Health
|
| 2:15 – 2:30 p.m. |
Q & A
|
| 2:30 – 3:15 p.m. |
Session 3
Drug Treatment as HIV Prevention
Chair: Frank Vocci, Ph.D.
National Institute on Drug Abuse
Does Treatment of Stimulant Use Disorders Reduce HIV Risk Behavior?
Richard Rawson, Ph.D.
University of California, Los Angeles
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction
Kenzie Preston, Ph.D.
Intramural Research Program
National Institute on Drug Abuse
Behavioral Therapy and HIV Risk Reduction: An International Perspective
Marek Chawarski, Ph.D.
Yale University
|
| 3:15 – 3:30 p.m. |
Q & A |
| 3:30 – 3:45 p.m. |
Break |
| 3:45 – 4:45 p.m. |
Session 4
Drug Abuse and HIV/AIDS: Women and Youth
Chair: Joseph Frascella, Ph.D.
National Institute on Drug Abuse
Do Sex and Drug Behavior Patterns Account for HIV/STD Racial Disparities?
Denise Hallfors, Ph.D.
University of North Carolina
Drug Use and the Health of HIV-Infected Youth
Jonathan Ellen, M.D.
Johns Hopkins University
How Does Trauma Contribute to Substance Abuse and HIV Infection Among Ethnic Women?
Gail E. Wyatt, Ph.D.
University of California, Los Angeles
Women Interagency HIV Study: Association of Substance Use With HIV Clinical Outcomes, Metabolic Conditions, and Psychiatric Comorbidity
Kathryn Anastos, M.D.
Albert Einstein College of Medicine
|
| 4:45 – 5:05 p.m. |
Q & A |
| 5:05 p.m. |
Adjourn for the Day |
Wednesday, May 9, 2007 |
| 8:30 – 8:45 a.m. | Welcome and Introduction
Jacques Normand, Ph.D.
National Institute on Drug Abuse
|
| 8:45 – 9:30 a.m. |
Session 5
HIV Prevention in Criminal Justice Populations
Chair: Redonna K. Chandler, Ph.D.
National Institute on Drug Abuse
HIV/AIDS and the Criminal Justice System
Theodore Hammett, Ph.D.
Abt Associates, Inc.
A Multisite HIV Prevention Protocol for Drug-Involved Offenders Returning to the Community
James Inciardi, Ph.D.
University of Delaware
HIV Testing Strategies and Linkage To Care for Criminal Justice Populations
Timothy Flanigan, M.D.
Brown Medical School
|
| 9:30 – 9:45 a.m. |
Q & A |
| 9:45 – 10:30 a.m. | Session 6
Testing and Counseling Policy
Chair: Timothy P. Condon, Ph.D.
National Institute on Drug Abuse
HIV Testing and Counseling: Public Health Impact
A. David Paltiel, Ph.D.
Yale University
CDC’s Recommendations for HIV Screening in Health Care Settings
Bernard Branson, M.D.
Centers for Disease Control and Prevention
Barriers to HIV/AIDS Care
Barbara Turner, M.D.
University of Pennsylvania
|
| 10:30 – 10:45 a.m. |
Q & A |
| 10:45 – 11:00 a.m. | Break |
| 11:00 – 11:45 a.m. | Session 7
Expanding HIV Testing and Counseling Into Community Settings
Chair: Betty Tai, Ph.D.
National Institute on Drug Abuse
Ethical Challenges for Research-Related HIV Testing and Counseling: Community Perspectives
Celia Fisher, Ph.D.
Fordham University
HIV Testing and Counseling in Drug Abuse Treatment
Jim Sorensen, Ph.D.
University of California, San Francisco
Voluntary Counseling and Testing: An International Randomized Community Trial
David Celentano, Sc.D.
Johns Hopkins University
|
| 11:45 a.m. – 12:00 noon |
Q & A |
| 12:00 noon – 12:15 p.m. | Wrap-Up
Jacques Normand, Ph.D.
National Institute on Drug Abuse
|
| 12:15 p.m. | Adjournment
|
|
|
